RxDoctor Payments Data

Michael Sampson

Nurse Practitioner · Longwood, FLNPI 1144528522

Payments from drug & device makers

$745in general payments, 2019–2025

Across 40 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$272
  • AstraZeneca$178
  • Boehringer Ingelheim$57
  • Paratek Pharmaceuticals, Inc.$39
  • Regeneron Healthcare Solutions, Inc.$38
  • Insmed, Inc.$34
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$72798%
  • Education$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$745 in reported general payments places this provider in the 70th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$34,518
Medicare patients
230
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter354$253,512
Breo ElliptaFluticasone/Vilanterol55$25,152
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$23,559
SymbicortBudesonide/Formoterol Fumarate59$23,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$23,055
Spiriva RespimatTiotropium Bromide13$14,141
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$13,193
Advair HfaFluticasone Propion/Salmeterol24$11,589
Spiriva HandihalerTiotropium Bromide12$7,880
Albuterol Sulfate HfaAlbuterol Sulfate220$6,839
Wixela InhubFluticasone Propion/Salmeterol29$4,024
Arnuity ElliptaFluticasone Furoate12$3,816
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,497
Ventolin HfaAlbuterol Sulfate35$2,743
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$2,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$272$306,039460 claims
AstraZenecaSymbicort, Breztri Aerosphere$178$46,48592 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$57$27,33437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Longwood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →